Eton Pharmaceuticals, Inc. (ETON) earnings date
Mar 18, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 44 days, typically, give or take 18 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 13, 2026 | after close | 44 | 8-K |
| Q1 FY2026 | Thu, May 14, 2026 | after close | 44 | 8-K |
| Q4 FY2025 | Thu, Mar 19, 2026 | after close | 78 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | after close | 38 | 8-K |
| Q1 FY2025 | Tue, May 13, 2025 | after close | 43 | 8-K |
| Q4 FY2024 | Tue, Mar 18, 2025 | before open | 77 | 8-K |
What they guided beta
| Q3 FY2026 | "Raised 2026 revenue guidance to more than $175 million, from prior guidance of more than $145 million; raised 2026 Adjusted EBITDA to more than 40%, from prior guidance of more than 35%" exhibit |
| Q3 FY2026 | "We are raising both our revenue and adjusted EBITDA guidance for 2026, reflecting the strong momentum in our business,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals." exhibit |
| Q3 FY2026 | "The Company expects continued organic growth from these products through the remainder of 2026 and beyond." exhibit |
| Q3 FY2026 | "Licensed product candidate ASN-001 and initiated bioavailability study, with first participant expected to be dosed in January 2027." exhibit |
| Q3 FY2026 | "With a bioavailability study underway, Eton anticipates submitting a New Drug Application (NDA) in 2027." exhibit |
| Q2 FY2026 | "Raising full year revenue guidance, with 2026 revenue now expected to exceed $145 million, up from previous guidance of more than $120 million" exhibit |
| Q2 FY2026 | "The Company plans to initiate a bioavailability study and anticipates a New Drug Application (“NDA”) submission upon the study’s completion in the second half of 2027." exhibit |
| Q2 FY2026 | "The product is FDA-approved, and Eton expects to begin commercializing the product in September 2026." exhibit |
| Q2 FY2026 | "The Company plans to initiate a bioavailability study for the product later this month and remains on track to submit an NDA by the end of 2026, allowing for potential approval and launch in 2027." exhibit |
| Q2 FY2026 | "If pilot study results are successful, Eton anticipates initiating a pivotal clinical study in early 2027." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ETON
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ETON
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/ETON/"><img src="https://veritasdata.dev/embed/ETON.svg" alt="ETON earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/ETON/)
Script
<script async src="https://veritasdata.dev/embed/ETON.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ETON"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.